Ipca Laboratories on Friday said it has entered into an agreement with Medicines for Malaria Venture to jointly develop a novel antimalarial co-formulation Atoguanil, which contains the active pharmaceutical ingredients atovaquone and proguanil.
“Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone-proguanil based products in malaria-endemic countries,” it added. Shareholders will closely monitor the developments.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.